Biopure's blood substitute Hemopure (hemoglobin glutamer - 250 [bovine])has been approved in South Africa for the treatment of acute anemia and avoidance of red blood cells in adult surgery patients. This is the first-ever approval of an oxygen therapeutic for human use, notes Biopure, which says it plans to file for registration of Hemopure in the USA later this year, with submissions in Europe and other countries following thereafter.
Hemopure will be marketed in South Africa by local companies Network Healthcare Holdings and Community Healthcare Holdings, via their joint subsidiary Tshepo Pharmaceuticals. Tshepo will launch the product in the first half of next year, once Biopure ramps up its production capacity for the drug. In the meantime, Biopure is making the drug available at no cost to select Netcare hospitals in South Africa.
Hemopure, which is based on purified hemoglobin derived from bovine red cells, is intended for use as an "oxygen bridge" to help stabilize anemic surgery patients until they manufacture their own red blood cells or compatible cells can be administered.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze